TransCelerate partners with Medidata to focus on risk-based monitoring

TransCelerate partners with Medidata to focus on risk-based monitoring

Medidata will provide metrics and analytics help to industry group TransCelerate to answer questions on the benefits and challenges associated with a risk-based approach to monitoring of clinical trial sites.

The partnership will look to analyze the relative contribution of source document verification (SDV) to overall clinical data quality through the use of Medidata’s software. The findings will be analyzed with the intent of publishing the results in a paper co-authored by TransCelerate and Medidata.

Lawrence Florin at Medidata explained to OutsourcingPharma.com that the analytics provider is looking to use its database prioritized for risk-based monitoring (RBM) to help TransCelerate make industry generalizations on distinct RBM methodologies. He also noted that there are members of the consortium using Medidata tools individually.

The analysis is being conducted via Medidata’s comprehensive business analytics tool, which comprises data—collected over the last five years—from over 7,000 clinical trials across the globe involving more than 120 sponsor organizations.

Non-profit industry group TransCelerate -- which includes member companies such as AstraZeneca, Eli Lilly, Johnson and Johnson and GlaxoSmithKline – is more broadly looking to help advance innovation in research and development.

Today we can leverage technology to change the model and find patterns of behaviour and confirm quality of performance at sites, and therefore assure the sponsors and CROs that patients are being managed properly,” Florin said. “At the end of the day, we’re looking for a mechanism to change behaviour and increase confidence that change in an approach can be comfortable.”

As CROs and sponsors turn to risk-based monitoring, there is an “enormous amount of runway in terms of gaining traction,” Florin added, as it’s “still very early in what companies are doing.”

Following draft guidance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), TransCelerate released a position paper in June 2013 and an update in early 2014 outlining an  approach for RBM that can be adopted for any type, phase and stage of a clinical trial. The framework provided includes tools and triggers to help the industry identify and categorize risks.

The industry group has launched pilot projects, the intent of which is to inform TransCelerate members on how well the methods and tools work.  On a quarterly basis, qualitative and quantitative feedback is proactively collected from member companies and then assessed for impact. TransCelerate expects there will be sufficient data in Q3 of 2014 to ensure these metrics are meaningful and worthy of sharing broadly.

In addition, Medidata and TransCelerate will publish a paper on the results that they’ve found, which Stephen Young at Medidata told us will hopefully come by the end of the summer.

Related News

Smartphone and tablet tool for clinical trial monitoring

New smartphone tool could aid clinical trial monitoring, says Endpoint

TransCelerate offers an update on its progress

TransCelerate stops short of offering membership to CROs

CRAs will seek to establish more relationships with sites as RBM progresses

Industry shift to risk-based monitoring will change roles of CRAs, experts say

Medidata's customer base grew to 437 companies, with 30 new clients added in Q2 of 2014

Medidata sees revenue growth in Q2 as new clients spike

All personal patient information and investigator names will be removed or redacted

TransCelerate recommends what to protect in trial transparency efforts

Two new publications from TransCelerate on RBM

TransCelerate hones in on two aspects of new risk-based monitoring methodology

Medidata hit by $4.8m wire fraud, but says customer data is safe

Medidata hit by $4.8m wire fraud, but says customer clinical trial data is safe

Forum to help CROs interact with TransCelerate

Forum to help CROs interact with TransCelerate

Pharma still not nice, but collaborating to fix trials says TransCelerate CEO

Collaboration can fix ‘broken’ clinical trials model TransCelerate CEO tells CROs

Partnership focuses on combo of mobile health, cloud-based tech

Partnership focuses on combo of mobile health, cloud-based tech

Medidata: More than just an Electronic Data Capture company, say analysts

Medidata widening the gap on trial data competitors, say analysts

Strongest growth for Medidata came from large and mid-sized biopharma customers in 2014

Medidata: Big Pharma drove sales but CRO partnerships rising

A look at the vivofits being used in clinical trials now

Medidata partners with Garmin to track patient activity in early clinical trials

TransCelerate launches two new initiatives to accelerate clinical trials

TransCelerate launches two new initiatives to accelerate clinical trials

CRO CTI Clinical expands use of Medidata's cloud-based tools

CRO CTI Clinical expands use of Medidata's cloud-based tools

Another CRO signs up to Medidata's cloud-based platform

Biorasi latest CRO to join Medidata's Rave party

Big Pharma Begins Mutually Recognizing GCP Training

Big Pharma Begins Mutually Recognizing GCP Training, Site Qualifications

Big Pharmas to battle R&D bottlenecks

Big Pharmas team to tackle trial bottlenecks

Medidata plans acquisitions to continue strong profit growth

SEC filing sparks speculation PE firm plans Medidata takeover

SEC filing sparks speculation PE firm plans Medidata takeover

Related Products

See more related products